What were the main business segments of Becton Dickinson in fiscal year 2004?

In fiscal year 2004, Becton Dickinson operated through three main segments: BD Medical, BD Diagnostics, and BD Biosciences. BD Medical focuses on medical devices for medication delivery and patient care. BD Diagnostics provides products for specimen collection and analysis, particularly for microbiology and infectious diseases. BD Biosciences offers tools for cell analysis to aid in research and disease management.

What significant corporate actions did BDX undertake in fiscal year 2004?

In fiscal year 2004, BDX acquired Atto Bioscience, Inc. to strengthen its BD Biosciences segment and announced plans to sell its Clontech unit, which was classified as discontinued operations. The company also repurchased approximately 2.1 million shares of its common stock during the quarter ended September 30, 2004, as part of an ongoing repurchase program.

What are the key legal matters BDX is currently involved in?

BDX is involved in several significant legal proceedings. These include numerous product liability lawsuits related to natural rubber latex gloves and accidental needlesticks. A notable event was the settlement of a lawsuit with Retractable Technologies, Inc. for $100 million in July 2004. The company is also responding to administrative subpoenas and is a defendant in patent infringement claims related to its products.

How does regulatory oversight affect BDX's operations?

BDX's medical technology products and operations are subject to significant regulation by agencies like the U.S. Food and Drug Administration (FDA) and similar international bodies. These regulations govern product development, testing, manufacturing, labeling, marketing, and distribution. Regulatory approval is required for most products, and ongoing compliance can impact development timelines, costs, and the continued availability of products. While BDX believes it is in material compliance, regulatory actions like product recalls or seizures are a potential risk.

BDX 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Becton, Dickinson and Company (BDX) filed its annual report for the fiscal year ended September 30, 2004. The company operates as a global medical technology firm across three primary segments: Medical, Diagnostics, and Biosciences. BD Medical focuses on devices for medication delivery, diabetes care, and surgical products. BD Diagnostics offers solutions for specimen collection and analysis, particularly in microbiology and infectious disease testing. BD Biosciences provides research and clinical tools for cell analysis, crucial for drug discovery and disease management. Key developments during the year included the acquisition of Atto Bioscience, Inc. to bolster the BD Biosciences segment, and the decision to divest the Clontech unit, which will be reported as discontinued operations. The company highlighted its commitment to research and development, investing approximately $236 million in fiscal year 2004. BDX also addressed ongoing litigation, including product liability cases related to latex gloves and needlestick injuries, as well as a significant settlement with Retractable Technologies, Inc. for $100 million. The company reported strong market presence and a diverse product portfolio, while acknowledging competitive pressures and regulatory oversight inherent in the medical technology sector.

Key Highlights

1BDX operates through three main segments: Medical, Diagnostics, and Biosciences, offering a diverse range of medical supplies, devices, laboratory equipment, and diagnostic products.

2The company made a strategic acquisition of Atto Bioscience, Inc. in July 2004 to enhance its capabilities in the BD Biosciences segment.

3BDX plans to divest its Clontech unit, which will be accounted for as discontinued operations.

4Research and development remains a key focus, with approximately $236 million invested in fiscal year 2004.

5The company is actively managing several significant legal proceedings, including product liability claims and a $100 million settlement with Retractable Technologies, Inc.

6BDX operates globally with manufacturing facilities in numerous countries across North America, Europe, Latin America, and Asia Pacific.

7The company is subject to extensive regulatory oversight from agencies like the FDA, impacting product development, manufacturing, and marketing.

BECTON DICKINSON & CO Annual Report, Year Ended Sep 30, 2004

Summary

Key Highlights

Frequently Asked Questions